Table 2.
Total costs, LYs and QALYs of all interventions for HBeAg positive CHB patients aged 30 years old and above
|
Interventions |
Total costs (THB) § | LYs | QALYs | Incremental cost (THB) | Incremental QALYs | ICER per QALY gained |
|---|---|---|---|---|---|---|
| First drug (Second drug) Third drug | ||||||
| 1. Generic lamivudine (tenofovir)† |
456,000 |
20.87 |
13.66 |
-72,000 |
5.03 |
Dominant* |
| 2. Generic lamivudine (tenofovir)‡ |
490,000 |
20.87 |
13.66 |
-38,000 |
5.03 |
Dominant* |
| 3. Tenofovir monotherapy† |
501,000 |
20.89 |
13.67 |
-26,000 |
5.04 |
Dominant* |
| 4. Palliative care |
527,000 |
13.13 |
8.63 |
- |
- |
- |
| 5. Original lamivudine (tenofovir)† |
937,000 |
20.87 |
13.66 |
409,000 |
5.03 |
81,000 |
| 6. Pegylated interferon (original lamivudine) tenofovir† |
953,000 |
20.89 |
13.67 |
426,000 |
5.05 |
84,000 |
| 7. Original lamivudine (tenofovir)‡ |
971,000 |
20.87 |
13.66 |
444,000 |
5.03 |
88,000 |
| 8. Generic lamivudine (adefovir)† |
982,000 |
20.87 |
13.66 |
454,000 |
5.03 |
90,000 |
| 9. Pegylated interferon (tenofovir)† |
1,057,000 |
20.91 |
13.69 |
530,000 |
5.06 |
105,000 |
| 10. Telbivudine (tenofovir)† |
1,091,000 |
20.90 |
13.68 |
564,000 |
5.05 |
112,000 |
| 11. Generic lamivudine (adefovir)‡ |
1,134,000 |
20.87 |
13.66 |
606,000 |
5.03 |
121,000 |
| 12. Telbivudine (tenofovir)‡ |
1,134,000 |
20.87 |
13.66 |
606,000 |
5.03 |
121,000 |
| 13. Pegylated interferon (original lamivudine) tenofovir† |
1,325,000 |
20.89 |
13.67 |
798,000 |
5.05 |
158,000 |
| 14. Adefovir (generic lamivudine)† |
1,364,000 |
20.85 |
13.64 |
837,000 |
5.01 |
167,000 |
| 15. Pegylated interferon (lamivudine) adefovir† |
1,371,000 |
20.89 |
13.67 |
844,000 |
5.05 |
167,000 |
| 16. Telbivudine (adefovir)† |
1,429,000 |
20.90 |
13.68 |
902,000 |
5.05 |
178,000 |
| 17. Pegylated interferon (telbivudine) tenofovir† |
1,442,000 |
20.92 |
13.69 |
915,000 |
5.06 |
181,000 |
| 18. Original lamivudine (adefovir)† |
1,463,000 |
20.87 |
13.66 |
936,000 |
5.03 |
186,000 |
| 19. Entecavir (tenofovir)† |
1,519,000 |
20.88 |
13.67 |
991,000 |
5.04 |
197,000 |
| 20. Entecavir (adefovir)† |
1,536,000 |
20.88 |
13.67 |
1,009,000 |
5.04 |
200,000 |
| 21. Adefovir (original lamivudine)† |
1,564,000 |
20.85 |
13.64 |
1,037,000 |
5.01 |
207,000 |
| 22. Original lamivudine (adefovir)‡ |
1,616,000 |
20.87 |
13.66 |
1,088,000 |
5.03 |
216,000 |
| 23. Pegylated interferon (adefovir) generic lamivudine† |
1,648,000 |
20.88 |
13.66 |
1,120,000 |
5.04 |
222,000 |
| 24. Telbivudine (adefovir)‡ |
1,657,000 |
20.90 |
13.68 |
1,130,000 |
5.05 |
224,000 |
| 25. Pegylated interferon (telbivudine) adefovir† |
1,710,000 |
20.92 |
13.69 |
1,182,000 |
5.06 |
233,000 |
| 26. Pegylated interferon (original lamivudine) adefovir† |
1,744,000 |
20.89 |
13.67 |
1,216,000 |
5.05 |
241,000 |
| 27. Pegylated interferon (entecavir) tenofovir† |
1,771,000 |
20.90 |
13.68 |
1,243,000 |
5.05 |
246,000 |
| 28. Pegylated interferon (entecavir) adefovir† |
1,785,000 |
20.90 |
13.68 |
1,257,000 |
5.05 |
249,000 |
| 29. Pegylated interferon (adefovir) original lamivudine† | 1,812,000 | 20.88 | 13.66 | 1,284,000 | 5.04 | 255,000 |
†Scenario 1: Adding drug when drug resistance occurred; ‡Scenario 2: Adding drug based on the road map guideline.
§total costs are calculated in 2010 THB and rounded up to nearest 1,000 THB.
*Negative ICER due to higher effectiveness and lower costs of intervention compared with palliative care.